碳青霉烯类抗生素用于医院获得性肺炎经验性治疗的系统评价与荟萃分析
本系统评价与荟萃分析纳入20项随机对照试验共5489例患者,比较碳青霉烯类与非碳青霉烯类方案经验性治疗医院获得性肺炎(含呼吸机相关性肺炎)的疗效。
要点
- 碳青霉烯类经验性治疗医院获得性肺炎可降低全因死亡率(RR 0.84)。
- 死亡率获益主要见于呼吸机相关性肺炎占比>66%的试验及APACHE II评分<18的患者。
核心结论
- 碳青霉烯类经验性方案较非碳青霉烯类方案与更低死亡率相关,该效应主要由呼吸机相关性肺炎试验驱动。
- 死亡率效应在高疾病严重度试验中未观察到,且与铜绿假单胞菌流行率无关。
- 死亡率差异主要见于使用头孢他啶作为对照的研究。
- 碳青霉烯类使用与耐药发生增加呈趋势相关。
研究设计与样本
- 系统评价与荟萃分析,检索随机对照试验,比较碳青霉烯类与非碳青霉烯类方案经验性治疗医院获得性肺炎和/或呼吸机相关性肺炎。
- 共纳入20项试验,5489例患者。
- 主要结局为全因死亡率,次要结局包括亚组分层和耐药发生。
临床怎么用
- 对于医院获得性肺炎/呼吸机相关性肺炎经验性治疗,碳青霉烯类方案可考虑用于降低死亡率,尤其呼吸机相关性肺炎占比较高的场景。
- 在高疾病严重度(APACHE II评分较高)患者中,碳青霉烯类的死亡率获益未观察到,需权衡使用。
- 使用碳青霉烯类时需关注耐药发生风险,尽管本分析中耐药增加仅为趋势。
局限性
- 死亡率获益主要来自呼吸机相关性肺炎试验及以头孢他啶为对照的研究,外推需谨慎。
- 未报告其他可能影响结论的异质性来源或偏倚风险评估细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous meta-analyses suggested that treating hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), with empiric carbapenems was associated with lower mortality rates but higher rates of clinical failure for pseudomonal pneumonia. This study was an updated meta-analysis with sensitivity analyses and meta-regression to better understand the impact of carbapenem use in HAP/VAP. RESEARCH QUESTION: What is the efficacy of carbapenems for empiric treatment of nosocomial pneumonia? STUDY DESIGN AND METHODS: Databases were searched for randomized controlled studies evaluating empiric treatment for HAP and/or VAP, and studies were included comparing carbapenem- vs non-carbapenem-containing regimens. The primary outcome was all-cause mortality. Secondary outcomes included subgroup stratification and resistance development. RESULTS: Of 9,140 references, 20 trials enrolling 5,489 patients met inclusion criteria. For mortality, carbapenem use had a risk ratio (RR) of 0.84 (95% CI, 0.74-0.96; P = .01). Stratified according to VAP proportion (< 33%, 33%-66%, and > 66%), RRs were 0.95 (95% CI, 0.77-1.17; P = .66), 0.78 (95% CI, 0.57-1.07; P = .13), and 0.81 (95% CI, 0.65-0.99; P = .04), respectively. Stratified according to severity, only groups with Acute Physiology and Chronic Health Evaluation II scores < 14 and between 14 and 17 showed mortality benefit (RRs of 0.64 [95% CI, 0.45-0.92; P = .01] and 0.77 [95% CI, 0.61-0.97; P = .03]). Meta-regression did not show an association between Pseudomonas prevalence and mortality (P = .44). Carbapenem use showed a trend toward developing resistance (RR, 1.40; 95% CI, 0.95-2.06; P = .09) and a 96% probability of resistance emergence. INTERPRETATION: Carbapenem-based empiric regimens were associated with lower mortality rates compared with non-carbapenems, largely driven by trials of VAP. The mortality effect was not observed in trials with high disease severity and was not associated with Pseudomonas. The mortality difference was observed mainly in studies that used ceftazidime as control. There was a trend toward increasing resistance associated with carbapenems. TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No. CRD42018093602; URL: https://www.crd.york.ac.uk/prospero/.
引用
- Howatt M, Klompas M, Kalil AC, et al. Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33393468. doi:10.1016/j.chest.2020.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。